Skip to main content

Advertisement

Table 1 Details of the 21-day interval chemotherapy regimen

From: Evaluating the analgesic effect and advantage of transcutaneous electrical acupoint stimulation combined with opioid drugs for moderate to severe cancer-related pain: a study protocol for a randomized controlled trial

Chemotherapy regimen Drugs Dosage Administration route Medication time
Combined chemotherapy
 NP Navelbine 25 mg/m2 i.v. D1, D8
Cis-platinum 80 mg/m2 i.v. D1
 TP Paclitaxel 135~175 mg/m2 i.v. D1
Cis-platinum 75 mg/m2 i.v. D1
or Carboplatin AUC = 5–6 mg/m2 i.v. D1
 GP Gemcitabine 1250 mg/m2 i.v. D1, D8
Cis-platinum 75 mg/m2 i.v. D1
or Carboplatin AUC = 5–6 mg/m2 i.v. D1
 DP Docetaxel 75 mg/m2 i.v. D1
Cis-platinum 75 mg/m2 i.v. D1
or Carboplatin AUC = 5–6 mg/m2 i.v. D1
 PC Pemetrexed 500 mg/m2 i.v. D1
Cis-platinum 75 mg/m2 i.v. D1
or Carboplatin AUC = 5–6 mg/m2 i.v. D1
 EP Etoposide 100 mg/m2 i.v. D1–3
Cis-platinum 80 mg/m2 i.v. D1
or Carboplatin AUC = 5–6 mg/m2 i.v. D1
 EP Etoposide 120 mg/m2 i.v. D1–3
Cis-platinum 60 mg/m2 i.v. D1
 IP Irinotecan 65 mg/m2 i.v. D1, D8
Cis-platinum 30 mg/m2 i.v. D1, D8
 AP Amrubicin 40 mg/m2 i.v. D1–3
Cis-platinum 60 mg/m2 i.v. D1
 XT Docetaxel 75 mg/m2 i.v. D1
Capecitabine 950 mg/m2 p.o. D1–14
 GT Paclitaxel 175 mg/m2 i.v. D1
Gemcitabine 1000~1250 mg/m2 i.v. D1, D8
 TC Docetaxel 75 mg/m2 i.v. D1
Cyclophosphamide 600 mg/m2 i.v. D1
 TAC Docetaxel 75 mg/m2 i.v. D1
Doxorubicin 50 mg/m2 i.v. D1
Cyclophosphamide 500 mg/m2 i.v. D1
Single-agent chemotherapy
 Doxorubicin Doxorubicin 75 mg/m2 i.v. D1
 Paclitaxel Paclitaxel 175 mg/m2 i.v. D1
 Docetaxel Docetaxel 80 mg/m2 i.v. D1
 Capecitabine Capecitabine 1000–1250 mg/m2 p.o. D1–14
 Herceptin Herceptin 6 mg/kg i.v. D21
  1. i.v. intravenous injection, p.o. per os (oral administration)